日本临床肿瘤学会胃肠道间质瘤(GIST)临床实践指南2022已根据2014年和2017年指南开发的思想手册发布。一个独立于修订工作组的专门小组进行了系统审查。由于GIST是一种罕见的肿瘤,临床证据不足以回答几个临床和背景问题。因此,在这些准则中,我们认为管理GIST的专家之间的共识,利弊之间的平衡,病人的愿望,医疗经济视角,等。是除了证据之外的重要考虑因素。尽管国家综合癌症网络(NCCN)和欧洲医学肿瘤学会(ESMO)也发布了GIST治疗指南,这些指南中提出的治疗方法与本指南中的治疗方法存在一些差异,因为各国之间的健康保险制度存在差异。
The Japan Society of Clinical Oncology Clinical Practice
Guidelines 2022 for gastrointestinal stromal tumor (GIST) have been published in accordance with the Minds Manual for
Guideline Development 2014 and 2017. A specialized team independent of the working group for the revision performed a systematic review. Since GIST is a rare type of tumor, clinical evidence is not sufficient to answer several clinical and background questions. Thus, in these
guidelines, we considered that
consensus among the experts who manage GIST, the balance between benefits and harms, patients\' wishes, medical economic perspective, etc. are important considerations in addition to the evidence. Although
guidelines for the treatment of GIST have also been published by the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO), there are some differences between the treatments proposed in those guidelines and the treatments in the present
guidelines because of the differences in health insurance systems among countries.